Table 3.
Clinical trials with MAGEs
MAGE | Tumor type | Phase | Intervention | Identifier | Status |
---|---|---|---|---|---|
A3 | Melanoma | I/II | MAGE-A3.A1 peptide and CpG7909 | NCT00145145 | Terminated |
A3 | Melanoma | II | GSK1203486A recombinant MAGE-A3 ASCI |
NCT00706238 | Terminated |
A3 | Melanoma | II | GSK2132231A, dacarbazine | NCT00849875 | Terminated |
A3 | Melanoma | III | GSK 2132231A | NCT00796445 | Terminated |
A3 | Lung | I | GSK1572932A, cisplatin, vinorelbine, radiotherapy | NCT00455572 | Terminated |
A3 | Lung | III | GSK1572932A | NCT00480025 | Terminated |
A3, A12 | Metastatic | I/II | anti-MAGE-A3/12 TCR, aldesleukin, cyclophosphamide, fludarabine | NCT01273181 | Terminated |
A3 | Melanoma | I/II | Enhanced TCR Transduced Autologous T Cells | NCT01350401 | Ongoing |
A3 | Multiple myeloma | I/II | Enhanced TCR Transduced Autologous T Cells | NCT01352286 | Ongoing |
A3, C2 | Melanoma | II | TriMix-DC and ipilimumab | NCT01302496 | Ongoing |
A3, C1 | Multiple myeloma | I | CT7, MAGE-A3, and WT1 mRNA- electroporated Langerhans cells (LCs) | NCT01995708 | Recruiting |
A3 | Metastatic | I/II | Anti-MAGE-A3-DP4 TCR, cyclophosphamide, fludarabine, aldesleukin | NCT02111850 | Recruiting |
A3 | Metastatic | I/II | MG1MA3 (MG1 Maraba/MAGE-A3 adenovirus vaccine) | NCT02285816 | Recruiting |
A10 | Urinary bladder, head and neck, melanoma | I | Autologous genetically modified MAGE A10C796T cells | NCT02989064 | Recruiting |
A10 | Lung | I/II | Autologous genetically modified MAGE A10C796T cells | NCT02592577 | Recruiting |
A3 | Lung | I/II | Ad-MAGEA3, MG1-MAGEA3, pembrolizumab | NCT02879760 | Recruiting |